The GHK Tripeptide

GHK (Gly-His-Lys) is a naturally occurring tripeptide found in human plasma, saliva, and urine. Its plasma concentration is highest in young adults (~200 ng/mL at age 20) and declines significantly with age (~80 ng/mL by age 60). When complexed with copper (Cu²⁺) to form GHK-Cu, the peptide takes on significantly enhanced biological activity. The copper ion is not incidental — it is central to the mechanism.

Mechanism: Copper Chelation & Bioavailability

GHK has a high affinity for Cu²⁺ ions, forming a stable chelate via its histidine imidazole ring and terminal amino group. This chelation serves two purposes: it makes copper bioavailable to cells (which cannot efficiently absorb free copper ions), and it modulates the peptide's receptor binding and activity. The GHK-Cu complex stimulates collagen, elastin, and glycosaminoglycan synthesis in fibroblasts; promotes angiogenesis; and activates metalloproteinase enzymes involved in tissue remodeling. It also activates antioxidant genes including superoxide dismutase (SOD1).

Injectable vs. Topical Research Models

GHK-Cu is studied in both injectable and topical formulations. Injectable research primarily targets wound healing, anti-inflammatory, and systemic regenerative models — subcutaneous injection is the most common route. Topical formulations are used in dermatology research for collagen synthesis, UV damage repair, and hair follicle research. Because the peptide is small (MW ~340 Da), topical penetration is reasonably efficient compared to larger peptides.

Purity & Copper Ratio Verification

GHK-Cu COAs should document both the peptide purity (HPLC ≥98%) and the copper content. The correct molar ratio is 1:1 (one copper ion per peptide molecule). Excess free copper would be cytotoxic; insufficient copper reduces efficacy. A complete COA from a qualified lab should report copper content alongside HPLC data. Mass spec should confirm MW of ~340.8 Da for the GHK-Cu complex.